Below we highlight few companies whose shares are actively trading in Thursday's session.
Las Vegas Sands Corp. (NYSE: LVS) slid more than 5% Thursday after Sands China Ltd., controlled by billionaire Sheldon Adelson’s casino company, said that it’s being investigated by the Hong Kong Securities and Futures Commission for alleged breaches of regulations.
Shares of CF Industries Holdings Inc. (NYSE: CF) rallied more than 4% after the government said farmers planned to plant more corn this spring than last.
Synthesis Energy Systems, Inc. (NASDAQ: SYMX) jumped more than 40% after the company announced that it has signed an agreement with China Energy Industry Holding Group Co., Limited, for a cash investment of approximately US$83.8 million to support the Company's business strategy in China, including project development and investment. China Energy, a Hong Kong based limited liability corporation, has been formed by Zhongjixuan Investment Management Ltd. of Beijing for the purpose of investing in SES.
Luna Innovations Incorporated (NASDAQ: LUNA) soared more than 54% after the company announced that it has agreed with Intuitive Surgical, Inc. (NASDAQ: ISRG), to extend its development efforts under its development and supply agreement with Intuitive towards further integrating Luna’s shape sensing technology into Intuitive’s products.
Prana Biotechnology (NASDAQ: PRAN) jumped more than 8% after the company announced that Alzheimer's Drug Discovery Foundation will provide Prana with a mission-related investment of US$700,000 over two years to conduct a clinical trial investigating the potential of PBT2 to reduce the accumulation of beta-amyloid in the brain of people with Alzheimer's Disease. Beta-amyloid is thought to be a cause of brain cell death and dementia in Alzheimer's Disease. The Phase II study will enroll 40 patients with mild AD for 12 months, with Positron Emission Tomography amyloid neuroimaging and other biomarkers as the primary outcome measures.
Radient Pharmaceuticals Corporation (AMEX: RPC) sank more than 26% after the company announced preliminary results from its clinical study conducted in collaboration with a well-recognized, large third-party not-for-profit group practice and its affiliates for the validation of RPC's US FDA-cleared Onko-Sure® in vitro diagnostic cancer test.
Full Disclosure: None.
